Literature DB >> 10959815

Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure.

S Krähenbühl1, S Brandner, S Kleinle, S Liechti, D Straumann.   

Abstract

We report on 3 siblings (2 females and 1 male) with chronic progressive external ophthalmoplegia (CPEO), compatible with inherited mitochondrial cytopathy. The younger of the two sisters died at the age of 37 due to progressive respiratory failure. The older one presented with a status epilepticus at the age of 39 and was treated with valproate. Five months after the start of treatment, she developed fulminant liver failure and died. The brother has suffered from CPEO since early childhood but has had so far no other symptoms of a mitochondrial disease. A muscle biopsy from the younger sister revealed ragged-red fibers and decreased activities of complex I and IV of the respiratory chain but no pathogenic mutations in the mitochondrial tRNA genes or in several locations in the coding region of the mitochondrial genome. In the older sister's liver (obtained post-mortem), mitochondrial DNA was fragmented and could not be investigated. The clinical presentation and the biochemical findings suggest that all 3 siblings suffered from a mitochondrial cytopathy. Since mitochondrial cytopathies and valproate-induced fulminant liver failure are both rare events, an association between them is likely. Mitochondrial diseases should therefore be considered as a risk factor for valproate-induced liver failure and be excluded before treatment with valproate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959815     DOI: 10.1034/j.1600-0676.2000.020004346.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  23 in total

Review 1.  Chronic progressive external ophthalmoplegia.

Authors:  Andrew G Lee; Paul W Brazis
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

2.  Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA.

Authors:  Chih-Ming Lin; Peterus Thajeb
Journal:  Metab Brain Dis       Date:  2007-01-17       Impact factor: 3.584

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 4.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Hepatotoxicity of New Oral Anticoagulants (NOACs).

Authors:  Evangelia Liakoni; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

6.  Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.

Authors:  Ayse L Mindikoglu; Dale King; Laurence S Magder; John A Ozolek; George V Mazariegos; Benjamin L Shneider
Journal:  J Pediatr       Date:  2010-12-16       Impact factor: 4.406

Review 7.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  Presentation and diagnosis of mitochondrial disorders in children.

Authors:  Mary Kay Koenig
Journal:  Pediatr Neurol       Date:  2008-05       Impact factor: 3.372

9.  Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

Authors:  K M Waldhauser; K Brecht; S Hebeisen; H R Ha; D Konrad; D Bur; S Krähenbühl
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 10.  Mechanisms of immune-mediated liver injury.

Authors:  David H Adams; Cynthia Ju; Shashi K Ramaiah; Jack Uetrecht; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2010-01-13       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.